Tandem Diabetes Care Shares Drop 12% After Private Placement for Senior Notes
By Chris Wack
Tandem Diabetes Care shares were down 12%, to $27.43, after the diabetes-technology company said it intends to offer $250 million of its convertible senior notes due 2029 in a private placement.
The stock closed Monday's session 13% higher, but is down 34% in the past 12 months.
Tandem said it intends to grant the initial purchasers of the notes an option to purchase up to an additional $37.5 million principal amount of notes.
The company expects to use the proceeds from the offering, together with cash on hand, to repurchase some 1.50% convertible senior notes due 2025 and to repurchase up to $30 million of its shares in privately negotiated transactions.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 05, 2024 12:44 ET (17:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk